B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

por Mateos, M, Hari, P, Bahlis, N, Chari, A, van de Donk, NWCJ, Dholaria, B, Garfall, AL, Goldschmidt, H, Kortüm, KM, Krishnan, A, Martin, T, Morillo, D, Oriol, A, Reece, D, Rodriguez, C, Rodríguez-Otero, P, San-Miguel, JF, Usmani, SZ, Verona, R, Lin, SXW, Prior, TJ, Wade, M, Weiss, B, Goldberg, JD, Askari, E
Publicado 2022

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)...

por Minnema, M.C., Chari, A., Touzeau, C., Schinke, C., Berdeja, J., Oriol, A., van, de Donk N., Otero, P.R., Askari, E., Mateos, M.V., Costa, L.J., Caers, J., Rasche, L., Krishnan, A., Vishwamitra, D., Ma, X., Qin, X., Gries, K.S., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J.D., Heuck, C., Miguel, J.S., Moreau, P.
Publicado 2023

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

por Mascarenhas, J, Kosiorek, H, Prchal, J, Yacoub, A, Berenzon, D, Baer, MR, Ritchie, E, Silver, RT, Kessler, C, Winton, E, Finazzi, MC, Rambaldi, A, Vannucchi, AM, Leibowitz, D, Rondelli, D, Arcasoy, MO, Catchatourian, R, Vadakara, J, Rosti, V, Hexner, E, Kremyanskaya, M, Sandy, L, Tripodi, J, Najfeld, V, Farnoud, N, Salama, ME, Weinberg, RS, Rampal, R, Goldberg, JD, Mesa, R, Dueck, AC, Hoffman, R
Publicado 2019